These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 17103262

  • 21. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.
    Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S.
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2137-42. PubMed ID: 16172222
    [Abstract] [Full Text] [Related]

  • 22. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients.
    Jernström H, Frenander J, Fernö M, Olsson H.
    Br J Cancer; 1999 Jul; 80(9):1453-8. PubMed ID: 10424750
    [Abstract] [Full Text] [Related]

  • 23. Statins and breast cancer in postmenopausal women without hormone therapy.
    Eaton M, Eklof J, Beal JR, Sahmoun AE.
    Anticancer Res; 2009 Dec; 29(12):5143-8. PubMed ID: 20044629
    [Abstract] [Full Text] [Related]

  • 24. Risk factors for estrogen receptor-positive breast cancer.
    Hwang ES, Chew T, Shiboski S, Farren G, Benz CC, Wrensch M.
    Arch Surg; 2005 Jan; 140(1):58-62. PubMed ID: 15655207
    [Abstract] [Full Text] [Related]

  • 25. The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival.
    Sener SF, Winchester DJ, Winchester DP, Du H, Barrera E, Bilimoria M, Krantz S, Rabbitt S.
    Am J Surg; 2009 Mar; 197(3):403-7. PubMed ID: 19245923
    [Abstract] [Full Text] [Related]

  • 26. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 27. Hormone replacement therapy and breast cancer risk in California.
    Coombs NJ, Taylor R, Wilcken N, Fiorica J, Boyages J.
    Breast J; 2005 Jul; 11(6):410-5. PubMed ID: 16297085
    [Abstract] [Full Text] [Related]

  • 28. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA.
    Arch Intern Med; 2006 Jul 24; 166(14):1483-9. PubMed ID: 16864758
    [Abstract] [Full Text] [Related]

  • 29. Lifetime alcohol intake and breast cancer risk.
    Terry MB, Zhang FF, Kabat G, Britton JA, Teitelbaum SL, Neugut AI, Gammon MD.
    Ann Epidemiol; 2006 Mar 24; 16(3):230-40. PubMed ID: 16230024
    [Abstract] [Full Text] [Related]

  • 30. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
    Jemal A, Ward E, Thun MJ.
    Breast Cancer Res; 2007 Mar 24; 9(3):R28. PubMed ID: 17477859
    [Abstract] [Full Text] [Related]

  • 31. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L, Dell'Aniello S, Assouline S, Suissa S.
    BJOG; 2008 Jan 24; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [Abstract] [Full Text] [Related]

  • 32. Breast cancer and HRT--what are the data?
    Bieber EJ, Barnes RB.
    Int J Fertil Womens Med; 2001 Jan 24; 46(2):73-8. PubMed ID: 11374658
    [Abstract] [Full Text] [Related]

  • 33. Plasma prolactin concentrations and risk of postmenopausal breast cancer.
    Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE.
    Cancer Res; 2004 Sep 15; 64(18):6814-9. PubMed ID: 15375001
    [Abstract] [Full Text] [Related]

  • 34. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 35. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk.
    Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG, Kritchevsky SB, Neugut AI, Gammon MD.
    Am J Epidemiol; 2007 May 15; 165(10):1187-98. PubMed ID: 17337757
    [Abstract] [Full Text] [Related]

  • 36. [Last word on hormone replacement and breast cancer?].
    Rookus MA, van Leeuwen FE, Hamerlynck JV.
    Ned Tijdschr Geneeskd; 1998 Jan 17; 142(3):111-3. PubMed ID: 9557006
    [Abstract] [Full Text] [Related]

  • 37. Hormone therapy and breast cancer: what factors modify the association?
    Gertig DM, Fletcher AS, English DR, Macinnis RJ, Hopper JL, Giles GG.
    Menopause; 2006 Jan 17; 13(2):178-84. PubMed ID: 16645531
    [Abstract] [Full Text] [Related]

  • 38. Hormone replacement therapy in breast cancer survivors.
    Xydakis AM, Sakkas EG, Mastorakos G.
    Ann N Y Acad Sci; 2006 Dec 17; 1092():349-60. PubMed ID: 17308160
    [Abstract] [Full Text] [Related]

  • 39. [Estrogen replacement therapy and breast cancer].
    Bakken K, Alsaker E, Eggen AE, Lund E.
    Tidsskr Nor Laegeforen; 2005 Feb 03; 125(3):282-5. PubMed ID: 15702147
    [Abstract] [Full Text] [Related]

  • 40. Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.
    Cerne JZ, Ferk P, Frkovic-Grazio S, Leskosek B, Gersak K.
    Climacteric; 2012 Feb 03; 15(1):68-74. PubMed ID: 22132797
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.